JPRN-UMIN000023277已完成1 期
Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer - Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer
Pharma Valley Center0 个研究点目标入组 9 人开始时间: 2016年7月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Serious complications (e.g. other active co-existing malignancies, brain metastases, and malignant coelomic fluid required drainage) 2. Medical treatment such as major surgery within 4 weeks, systemic chemotherapy within 2 weeks. 3. Grade >=2 peripheral neuropathy 4. Administration of blood transfusion or G-CSF within 2 weeks 5. Thromboembolism (grade 3 or higher) within 6 months 6. Patient who is judged by the investigator to be inappropriate for study participation for any reason.
研究者
相似试验
招募中
2 期
Phase II study of FOLFIRI+Ramucirumab with early recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin / fluoropyrimidine(RAINCLOUD)Colorectal CancerJPRN-UMIN000028677MCSGO: Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group48
已完成
2 期
Phase II trial of FOLFOXIRI + Bevacizumab in patients with untreated metastatic colorectal cancerPatients with metastatic colorectal cancerJPRN-UMIN000017102Translational Research Informatics Center, Foundation for Biomedical Research and Innovation45
已完成
2 期
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer(WJOG9216G)first-line treatment in patients with metastatic colorectal cancerJPRN-UMIN000026527West Japan Oncology Group120
进行中（未招募）
2 期
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer (WJOG9216G)JPRN-jRCTs041180166Kito Yosuke120
已完成
1 期
Phase I study of FOLFOXIRI+cetuximab in patients with RAS wild-type unresectable colorectal cancerRAS wild-type unresectable colorectal cancerJPRN-UMIN000015620Aichi Cancer Center Hospital12